Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 500 clinical trials
Safety and Efficacy Study of SAR442720 in Combination With Other Agents in Advanced Malignancies

Primary Objectives: Part 1 To characterize the safety and tolerability of SAR442720 in combination with pembrolizumab in participants with advanced solid tumors. To define the MTD and RP2D for the combination of SAR442720 and pembrolizumab in participants with solid tumors. Part 2 To determine the anti-tumor activity of SAR442720 in …

measurable disease
cancer
KRAS
BRAF
  • 0 views
  • 08 Jul, 2022
  • 18 locations
LIVACOR Trial: Minimally Invasive LIVer And Simultaneous COlorectal Resection (LIVACOR)

The LIVACOR - Trial is a European wide, randomized controlled, open-label, multicenter trial. Patients with synchronous colorectal liver metastases (CRLMs) and primary colorectal tumor are considered eligible and will be randomized between minimally invasive (MI) combined or staged colorectal resection (all colectomies, including high anterior resection) and liver resection of …

carcinoma
  • 1 views
  • 11 Aug, 2022
  • 11 locations
Dose Efficiency of Modern CT Scanners in Oncologic Scans

CT-Staging is crucial for therapy planning of patients with malignancies. Dose efficiency and image quality are important parameters for these examinations. Up to now, scientific evidence of dose efficiency of modern CT scanners is mostly derived from retrospective analyses. This prospective study systematically analyzes dose efficiency and image quality of …

primary cancer
  • 0 views
  • 26 Aug, 2021
  • 1 location
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer (SABR-COMET-3)

Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques. SABR is non-invasive and delivered on an outpatient basis. The purpose of this study is to compare the effect of SABR, relative to standard of care (SOC) …

cancer
fdg-pet
positron emission tomography
primary tumor
stereotactic body radiation therapy
  • 88 views
  • 15 Jul, 2022
  • 14 locations
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors (SABR-COMET 10)

In patients with a limited oligometastatic burden (cancer has spread but is not yet considered metastatic), emerging evidence suggests that treatment of all sites of disease with ablative therapies can improve patient outcomes, including overall- and progression-free survival. The application of Stereotactic Ablative Radiotherapy (SABR) for patients with 4-10 metastatic …

cancer
stereotactic body radiation therapy
primary tumor
metastasis
  • 42 views
  • 29 Jul, 2022
  • 13 locations
An Open-Label, Multicenter Extension Study of Trastuzumab Emtansine Administered as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd-Sponsored Trastuzumab Emtansine Study

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this …

cancer
trastuzumab
paclitaxel
docetaxel
cancer treatment
  • 353 views
  • 14 Sep, 2022
  • 2 locations
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO (MOIO)

Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers

brain metastases
carcinoma
lung cancer
bevacizumab
pemetrexed
  • 0 views
  • 09 Jul, 2022
  • 19 locations
Safety and Efficacy Study of SAR442720 in Combination With Other Agents in Advanced Malignancies

Primary Objectives: Part 1 To characterize the safety and tolerability of SAR442720 in combination with pembrolizumab in participants with advanced solid tumors. To define the MTD and RP2D for the combination of SAR442720 and pembrolizumab in participants with solid tumors. Part 2 To determine the anti-tumor activity of SAR442720 in …

cancer
solid neoplasm
KRAS
measurable disease
pembrolizumab
  • 68 views
  • 21 Jul, 2022
  • 18 locations
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy (EMBER-3)

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have breast …

HER2
fulvestrant
exemestane
hormone therapy
estrogen
  • 12 views
  • 19 Sep, 2022
  • 183 locations
A Study to Test Different Doses of BI 1810631 in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful. The second part is open to people with non-small cell lung cancer with a specific mutation in …

brain metastases
HER2
lung cancer
egfr t790m
lung carcinoma
  • 0 views
  • 26 Jul, 2022
  • 6 locations